Memorial Sloan Kettering Cancer Center: Potential treatment of COVID-19 using inhalable camostat/nafamostat formulated with HPBCD or SBECD
Memorial Sloan Kettering Cancer Center (MSKCC) has filed a patent application on an inhalational therapeutic composition of camostat solubilized by